InvestorWire NewsRoom

Article

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments
June 24, 2021

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

  • Decision represents opportunity to help millions suffering from social, generalized anxiety disorders
  • Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward
  • WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant growth projected looking forward.

“The decision to pursue anxiety-disorder indications for CYB004 follows months of thoughtful, in-depth work by the Cybin development team,” said Cybin CEO Doug Drysdale. “Careful consideration of many factors drives these decisions, including the prevalence of anxiety disorders, the measurable clinical endpoints, a realistic preclinical and clinical plan, along with an understanding of the effects of the molecule itself. For the Cybin team, this decision represents a further opportunity to help millions of sufferers of these all-too-prevalent disorders.”

SAD, sometimes called social phobia, is categorized as the persistent and irrational fear of embarrassment and humiliation in social situations, and it is estimated to impact 3% to 7% of adults in the United States. The disorder often begins in childhood or adolescence and can contribute to major depression, substance abuse and other mental health problems. The disorder can be associated with extensive functional impairment and reduced quality of life.

An estimated 3% to 6% of the U.S. adult population suffers with GAD, experiencing excessive anxiety and worry (apprehensive expectation) about a range of everyday topics/events. The disorder is one of the most common mental disorders identified in both community and clinical settings and is associated with increased use of health care services.

“Based on estimates derived from currently available FDA-approved treatments, the current U.S. market is estimated at $165M with global estimates at $1.15B as of 2021,” the company announced. “The market is currently made up of multiple approved drugs still under patent protection, generics and off label use drugs.

For the gad market, “current global estimates are approximately $2.99 billion and projected to grow to $4.5B by 2027,” the announcement continued. “The market is currently made up of multiple approved drugs still under patent protection, generics and off label use drugs, including benzodiazepines that carry a risk of addiction, misuse and dependence.

The World Health Organization (“WHO”) estimates that 1 in 13 adults globally suffers from anxiety; however, current FDA-approved medications for anxiety disorders have slow onset of action with side effects that include weight gain, nausea, vomiting and sexual dysfunction. What’s more, many patients see no benefit from the treatments. However, studies evaluating the treatment of anxiety with psychedelics indicate a significant response to therapy, including a faster onset of action with less addictive effects. 

“People struggle with many different mental health challenges, but anxiety affects more people than any other,” explained Cybin chief clinical officer Dr. Alex Belser. “With the advent of the COVID-19 pandemic, rates of anxiety have increased threefold, leaving many folks in a debilitating state. We think that treatment with psychedelic medicine may help. 

“Our team’s previous research on anxiety at New York University and the trials conducted at UCLA and Johns Hopkins showed large magnitude decreases in anxiety after treatment with psychedelic-assisted psychotherapy,” he continued. “This is a promising approach to treat anxiety with a clear pathway.”

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).